# A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

> **NCT05448599** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** 6MW3211 injection with Intravenous Infusion

## Key facts

- **NCT ID:** NCT05448599
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-08
- **Primary completion:** 2024-06
- **Final completion:** 2024-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05448599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05448599, "A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05448599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*